Phosphate Therapeutics Selects Clinipace Worldwide To Manage Its Phase 2 Renal Study
2/12/2014 9:35:27 AM
MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Phosphate Therapeutics, co-owned and resourced by Shield Therapeutics (Shield), an independent specialty pharmaceutical company, has selected the company to manage its first pivotal trial in its late stage Nephrology program expected to commence in 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by